Myeloma UK has launched a new research programme to continue providing support to patient-centric myeloma clinical trials in the country – the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme (UKMRA-Myeloma UK-CARP).

The UKMRA-Myeloma UK-CARP is claimed to be an evolution of the Myeloma UK Clinical Trials Network (CTN), which was launched in 2009 and  led to the delivery of nine early phase clinical trials, and with more than 700 patients participating in these trials.

This initiative is intended to enable UK myeloma patients to access new treatments or treatment combinations as part of trials.

UKMRA-Myeloma UK-CARP will provide support to the development of studies that either offer a proof of concept data for larger and later phase trials, or data that can be used to support patients securing access to treatments through the NHS.

Part of the programme will be an exploration of ‘adaptive trials’, an innovation which enable researchers to learn from patient responses to treatment during the trial and gives them flexibility in order to adapt the treatment.

Through this new collaborative model, patient insight from Myeloma UK is brought together with the experience and expertise of the UK Myeloma UK Research Alliance and the University of Leeds Clinical Trials Research Unit (CTRU) to develop a portfolio of early phase clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The investment from Myeloma UK will help boost trial development and facilitate funding from external sources such as pharmaceutical companies and diagnostics companies in order to support the delivery of innovative trials developed through the UKMRA-Myeloma UK-CARP.

UKMRA chair professor Gordon Cook said: “Building on what has already been achieved through the Myeloma UK Clinical Trials Network we can develop a strong portfolio of early-phase trials through UKMRA-Myeloma UK-CARP and crucially, link these directly to the development of late-phase trials through the UKMRA to change clinical practice and patient outcomes.”